Syringe Exchange and Risk of Infection With Hepatitis B and C VirusesAbstracted from the American Journal of Epidemiology Online, Vol. 149, No. 3
February 4, 1999 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Abstract:Research conducted as part of the Risk Activity Variables, Epidemiology, and Network Study of intravenous drug users involved in a Seattle-King County, Wash., needle-exchange program indicates that the program was not effective in reducing hepatitis B virus (HBV) or hepatitis C virus (HCV) among the users. The authors of the study note that, while uncontrolled confounding or other bias may have obscured a beneficial impact, the study of 187 HCV-seronegative and 460 HBV-seronegative IDUs did not suggest such an effect. The participants were enrolled in the study between June 1994 and January 1996 and followed for seroconversion one year later. At follow up, there were 39 HCV infections and 46 HBV infections, the researchers report. A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. Visit the CDC's website to find out more about their activities, publications and services.
|
|